Results 81 to 90 of about 480,865 (305)

Activation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomach

Исследования и практика в медицине, 2019
Purpose of the study. The purpose of the study was to find the difference between local levels of VEGF, EGF, IGFI and IG- FII in tumor and intact tissues in adenocarcinoma of the stomach (AC) and signet-ring cell carcinoma of the stomach (SRCC).Materials
O. I. Kit, E. M. Frantsiyants, I. A. Goroshinskaya, E. I. Surikova, V. A. Bandovkina, Yu. A. Pogorelova, L. A. Nemashkalova, D. E. Medvedeva, E. V. Shalashnaja, A. A. Maslov, Yu. S. Sidorenko   +10 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Structure and molecular interaction analysis of monoclonal antibodies in complex with receptor tyrosine kinases [PDF]

, 2010
Misregulated receptor tyrosine kinases (RTKs), i.e. the epidermal growth factor receptor EGFR or the insulin-like growth factor receptor 1 (IGF-1R), can be involved in the development of cancer.
Schmiedel, Judith
core  

EGFR-Targeted Liposomes Combined with Ginsenoside Rh2 Inhibit Triple-Negative Breast Cancer Growth and Metastasis

, 2023
Triple-negative breast cancer (TNBC) remains the most challenging breast cancer subtype due to its lack of targeted therapies and poor prognosis. In order to treat patients with these tumors, efforts have been made to explore feasible targets.
Aiguo Wu (315321), Canxin Xu (3847465), Aiguo Wu, Yuanbo Pan, Rui Shi, Chen Xu (53797), Wenhao Lv (10914291), Xueyin Hu, Xueyin Hu (14034184), Wenhao Lv, Chen Xu, Canxin Xu, Juan Li, Haiyan Gu, Xiahong He, Rui Shi (45165), Xiahong He (369038), Juan Li (146180), Haiyan Gu (9726796), Yuanbo Pan (14034181)   +19 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Going beyond EGFR

Annals of Oncology, 2012
a substantial proportion of non-small-cell lung cancer (NSCLC), and adenocarcinoma in particular, depends on a so-called 'driver mutation' for their malignant phenotype. This genetic alteration induces and sustains tumorigenesis, and targeting of its protein product can result in growth inhibition, tumor response and increased patient survival.
Zimmermann, S., Peters, S.
openaire   +4 more sources

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Therapeutics and Clinical Risk Management, 2017
Wolfgang Hohenforst-Schmidt,1 Paul Zarogoulidis,2 Michael Steinheimer,1 Naim Benhassen,3 Chrysanthi Sardeli,4 Nikos Stalikas,2 Melpomeni Toitou,2 Haidong Huang5 1Sana Clinic Group Franken, Department of Cardiology/Pulmonology/Intensive Care/Nephrology, &
Hohenforst-Schmidt W, Zarogoulidis P, Steinheimer M, Benhassen N, Sardeli C, Stalikas N, Toitou M, Huang H   +7 more
doaj  

Synthesis of indolinone-based derivatives for liposomal insertion in active targeting against EGFR.

, 2022
reservedSulla base dei risultati ottenuti a seguito di un precedente progetto di ricerca svolto presso il Dipartimento di Scienze del Farmaco, l'obiettivo di questo lavoro di tesi sperimentale consta nella sintesi di derivati a base indolinonica ...
NEGRI, STEFANO
core